OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF PATIENTS WITH CHRONIC ABACTERIAL PROSTATITIS
DOI:
https://doi.org/10.55640/Keywords:
Chronic abacterial prostatitis, diagnosis, multimodal therapy, prostate, treatment, NIH-CPSI, quality of life.Abstract
Chronic abacterial prostatitis (CAP) is one of the most complex and insufficiently studied diseases of the male urogenital system. This condition is characterized by prolonged pain syndrome, urinary dysfunction, decreased sexual activity, and negative effects on the psychoemotional state of patients. According to statistical data, approximately 80–90% of all prostatitis cases are represented by the abacterial form. The multifactorial etiology and pathogenesis of the disease, as well as the absence of a clearly identified microbiological cause, complicate the diagnostic and therapeutic process. Therefore, optimizing the diagnosis and treatment of patients with CAP remains one of the most pressing challenges in modern urology.
Downloads
References
1.Krieger J.N., Nyberg L., Nickel J.C. Epidemiology of prostatitis. International Journal of Antimicrobial Agents, 2008.
2.National Institutes of Health. Classification of prostatitis. NIH Consensus Development Panel, 1999.
3.Anderson R.U., Wise D., Sawyer T., Chan C.A. Myofascial pain syndrome and chronic prostatitis. Journal of Urology, 2011.
4.Litwin M.S., McNaughton-Collins M., Fowler F.J. et al. The NIH Chronic Prostatitis Symptom Index. Journal of Urology, 1999.
5.Nickel J.C. Management of chronic prostatitis/chronic pelvic pain syndrome. Urology, 2013.
6.Shoskes D.A., Berger R., Elmi A. et al. Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Current Urology Reports, 2015.
7.Wagenlehner F.M.E., Pilatz A., Weidner W. Chronic prostatitis/chronic pelvic pain syndrome: which therapies are effective? European Urology, 2016.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India